

# Insulin sensitivity in preterm appropriate-for-gestational-age and small-for-gestational-age infants

<b>Submission date</b> 26/02/2007	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 26/02/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 26/08/2021	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof H P Sauerwein

**Contact details**  
Academic Medical Centre (AMC)  
Department of Endocrinology and Metabolism, F5-170  
P.O. Box 22660  
Amsterdam  
Netherlands  
1100 DD  
+31 (0)20 566 3061  
h.p.sauerwein@amc.uva.nl

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**Protocol serial number**  
NL874 (NTR888)

# Study information

## Scientific Title

Insulin sensitivity in preterm appropriate-for-gestational-age and small-for-gestational-age infants

## Study objectives

Insulin sensitivity is already reduced at birth in preterm Small-for-Gestational-Age (SGA) infants, compared to preterm Appropriate-for-Gestational-Age (AGA) infants.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approval received from the Central Committee on Research inv. Human Subjects on the 30th January 2006 (ref: P05.1488C).

## Study design

Observational study

## Primary study design

Observational

## Study type(s)

Other

## Health condition(s) or problem(s) studied

Small for gestational age, prematurity, insulin sensitivity

## Interventions

Methods used:

1. Glucose concentration: this will be measured with the glucose oxidase method using a Beckman Glucose Analyzer 2 (Beckman, Fullerton, CA)
2. Insulin: this will be determined with a chemiluminescent immunometric assay (Immulite 2000, Diagnostic Products Corporation, Los Angeles, USA)
3. Free Fatty Acid (FFA) concentration: this will be determined with an enzymatic colorimetric method (NEFA-C test kit, Wako Chemicals GmbH, Neuss, Germany)
4. Cortisol: this will be determined with a chemiluminiscent immunoassay (Immulite 2000, Diagnostic Products Corporation, Los Angeles, USA)
5. Adiponectin: this will be determined by a radioimmunoassay (Linco, St. Charles, USA)
6. Stable isotope measurements: Newborns are infused with [U-13C] glucose and [2-13C] glycerol. Isotope dilution and label incorporation will be determined by gas chromatography mass spectrometry (GCMS) and mass isotopomer distribution analysis (MIDA) in glucose, isolated from plasma

Calculations:

1. Rate of appearance (Ra) of glucose during steady state is calculated by the isotope dilution technique from the [U-13C] enrichment of glucose, using calculations for steady state kinetics, adapted for the use of stable isotopes:  $Ra = (E_i/E_p) \times I$ , where  $E_i$  and  $E_p$  are the enrichments of infusate and plasma respectively, and  $I$  is the infusion rate of [U-13C] glucose

2. Rate of disappearance (Rd): rate of exogenous glucose infusion plus the rate of endogenous glucose production
3. Endogenous glucose production: Rate of appearance minus rate of exogenous glucose infusion
4. Absolute gluconeogenesis: fractional gluconeogenesis (measured by MIDA) times rate of appearance
5. Glycogenolysis: Endogenous glucose production minus absolute gluconeogenesis

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Rate of appearance and disappearance of glucose during insulin infusion

**Key secondary outcome(s)**

1. Rate of gluconeogenesis and glycogenolysis
2. Plasma Free Fatty Acid (FFA) concentrations
3. Plasma concentrations of insulin, cortisol and adiponectin

**Completion date**

01/04/2008

**Eligibility****Key inclusion criteria**

1. Premature infants 28 to 32 weeks gestational age
2. Presence of a (central) venous and arterial catheter for clinical reasons
3. For preterm SGA infants: growth retardation caused by placental insufficiency, assessed by maternal history (pregnancy induced hypertension, preeclampsia), and confirmed by Doppler flow measurements of the umbilical arteries (Pulsatility Index [PI] more than +2 Standard Deviation [SD] for gestational age, measured on two occasions)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Neonate

**Sex**

Not Specified

**Key exclusion criteria**

1. For preterm SGA infants: growth retardation based on other causes (e.g. congenital infections, congenital malformations)

2. Major congenital malformations
3. Severe perinatal asphyxia defined as five minute Apgar score less than seven
4. Severe disturbances of glucose metabolism (glucose intake less than 4 or more than 8 mg.kg-1.min-1, or need for insulin therapy to maintain the glucose concentration between 2.6 and 8 mmol /l)
5. Severe respiratory distress. Mild ventilatory support is allowed:
  - a. nasal Continuous Positive Airway Pressure (nCPAP) with maximum Fraction of Inspired Oxygen (FiO2) of 0.40, maximum Positive End Expiratory Pressure (PEEP) 6 cm Water (H2O)
  - b. Synchronised Intermittent Mandatory Ventilation (SIMV) with maximum inspiratory peak pressure of 18 cm H2O and maximum FiO2 of 0.40
  - c. High Frequency Oscillatory Ventilation (HFOV) with maximum continuous distending pressure of 12 cm H2O and maximum FiO2 of 0.30
6. Need of vasopressor support for hypotension
7. Treatment with systemic corticosteroids
8. Clinical or laboratory evidence of sepsis: lethargy or irritability, hypo- or hyperthermia, temperature instability, tachypnea, apnea, bradycardia, hypotension, gastric retention, abdominal distension, pallor, elevated C- Reactive Protein (CRP)-level, leukocytosis or leukocytopenia and increased number of band neutrophils
9. Low haemoglobin level at the study days with need for a blood transfusion
10. Positive family history for type two diabetes in first degree relatives
11. No informed consent from parents or legal guardians

**Date of first enrolment**

01/04/2007

**Date of final enrolment**

01/04/2008

## Locations

**Countries of recruitment**

Netherlands

**Study participating centre**

**Academic Medical Centre (AMC)**

Amsterdam

Netherlands

1100 DD

## Sponsor information

**Organisation**

Diabetes Fonds Nederland (The Netherlands)

**ROR**

<https://ror.org/04ch2g225>

## **Funder(s)**

### **Funder type**

Hospital/treatment centre

### **Funder Name**

Academic Medical Centre (AMC) (The Netherlands)

## **Results and Publications**

### **Individual participant data (IPD) sharing plan**

#### **IPD sharing plan summary**

Not provided at time of registration